“…Several other papers tried to answer this question in their trials. For example, in the BITCOIN trial ( 17 ), out of 286 biliary tract cancer cases analyzed, the 24 patients (8.4%) with FGFR2/3 alteration had a better OS compared to FGFR wild-type cases (29.2 vs 14.4 months, p = 0.003). Focusing on the 183 iCCAs, the BITCOIN trial provided OS data from the time of the start of first-line therapy in patients with FGFR2-fusions (13 patients, with 11 undergoing 1st line treatment, OS 29.2 vs 15.0 months, p = 0.03) and in patients with all type pf FGFR2/3 alterations (19 cases, with 17 included in the analysis, OS 24.9 vs 14.8 months, p = 0.02); notably, the survival advantage held true even when censoring the 8 cases who received FGFR targeted therapies (HR = 0.32, 95% CI 0.12–0.85, p = 0.02).…”